An early FDA approval, an inhaled therapy being turned away by regulators for a third time, and three positive clinical updates are this week's top biotech stories.
Tesaro, Alnylam, Allergan, and Valeant could make waves across the health-care sector this morning.
These three biotech stocks have had a rough go over the past month, but can they make investors rich through the rest of 2014?
See which companies suffered the worst clinical setbacks in the week ending April 4.
MannKind, GlaxoSmithKline, Myriad Genetics, and Alnylam Pharmaceuticals could all make waves in the biotech sector this morning.
High cholesterol therapies could be ready to take a gigantic leap forward with the introduction of this new class of drugs.
See which companies scored big in the clinic.
Two regulatory actions, four mammoth clinical study updates, and an intriguing immunotherapeutic collaboration, are this week's most important biotech stories.
Alexion's valuation doesn't seem unreasonable relative to the significant sales growth opportunities still in front of the company
After an awesome 2013, Celgene (NASDAQ: CELG) has made a bad start to the year. Can it recover?